B. Braun Avitum AG and CytoSorbents Corporation Announce Global Co-Marketing Agreement to Promote the OMNI® Continuous Blood Purification Platform with CytoSorb®
Media
Links
Joint marketing of CytoSorb® with B. Braun’s newest OMNI® blood purification platform will offer greater access of this advanced treatment of deadly inflammation to critically ill patients.
MELSUNGEN, GERMANY and MONMOUTH JUNCTION, N.J., March 2, 2021 – B. Braun Avitum AG, a leading manufacturer of medical devices and pharmaceutical products and services and CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation, announce the launch of a global co-marketing agreement to promote the use of CytoSorb® with B. Braun’s latest OMNI® continuous blood purification platform and OMNIset® Plus bloodline set (set version 3.0 or higher).
CET- Comunicado - ;ultimaHoraHtml += + json.lead + ;}ultimaHoraHtml += ; document.getElementById( urgente ).innerHTML = ultimaHoraHtml; } } });
The CytoSorb adsorber is used in critical care for the extracorporeal removal of cytokines and inflammatory mediators from the bloodstream./ - CYTOSORBENTS
B. Braun Avitum AG and CytoSorbents Corporation Announce Global Co-Marketing Agreement to Promote the OMNI Continuous Blood Purification Platform with CytoSorb Joint marketing of CytoSorb with B. Braun s newest OMNI blood purification platform will offer greater access of this advanced treatment of deadly inflammation to critically ill patients.
MELSUNGEN, GERMANY and MONMOUTH JUNCTION, N.J., March 2, 2021 / News Aktuell- B. Braun Avitum AG, a leading manufacturer of medical devices and pharmaceutical products and services and CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its C
PhilHealth officials face graft raps at Ombudsman over reimbursement scheme
enablePagination: false
endIndex:
Metro Manila (CNN Philippines, January 12) The National Bureau of Investigation has filed a new complaint against former Philippine Health Insurance Corp. chief Ricardo Morales and other PhilHealth officials before the Office of the Ombudsman over irregularities in the release of the state insurer s funds.
The NBI on Monday recommended the charges for alleged violation of the Anti-Graft and Corrupt Practices Act, Misappropriation of Funds of the Corporation, and administrative cases of Grave Misconduct, Gross Negligence and Conduct Prejudicial to Public Interest. Aside from Morales, respondents to the case were executive vice presidents Arnel de Jesus and Renato Limsiaco, senior vice president Israel Pargas, and 11 other officials from Metro Manila and other regions.
PhilHealth, private healthcare officials slapped with charges
THE National Bureau of Investigation (NBI) on Monday filed new criminal and administrative complaints against officials of the Philippine Health Insurance Corp. (PhilHealth) over alleged irregularities in a financial assistance program for health care institutions hammered by “fortuitous” events like the coronavirus pandemic.
The NBI filed the complaints before the Office of the Ombudsman against resigned PhilHealth president and chief executive officer Ricardo C. Morales, among other former and current officials, for alleged violation of the Anti-Graft and Corrupt Practices Act.
The respondents also face raps for allegedly misappropriating funds in violation of the National Health Insurance Act of 2013. They also face administrative charges of grave misconduct, gross negligence, and conduct prejudicial to public interest.